Repeated administration of naltrexone and diprenorphine decreases food intake and body weight in squirrel monkeys.
Although chronic administration of naloxone has been reported to reduce food intake and body weight in rats, there have been no comparable investigations using a nonhuman primate. We examined the effects of repeated injections of two long acting opiate antagonists - naltrexone and diprenorphine - on the ad libitum intake of a nutritional complete liquid diet and on body weight in squirrel monkeys. Naltrexone binds with highest affinity to the mu opioid receptor whereas diprenorphine binds with equally high affinity to several subtypes of opioid receptor. Diprenorphine (ED50 = 0.01 mg/kg) was 22 times more potent than naltrexone (ED50 = 0.22 mg/kg) in decreasing 2 h food intake, suggesting that more than one opioid receptor subtype may be involved in the anorectic effects of opiate antagonists. A 1.0 mg/kg dose of drug reduced 24 h food intake by 50% and was associated with a weekly reduction in body weight of 4 and 5% for naltrexone and diprenorphine, respectively. Thus, in contrast with shorter time intervals, 24 h food intakes were similar for the two drugs, and this was associated with comparable body weight profiles. The decreases in food intake and body weight remained constant over the period of drug administration. Some monkeys showed profuse salivation and "wet dog shakes" after 4 days of treatment with the 1.0 mg/kg dose but not after 1 day. Therefore, opiate antagonists given chronically to monkeys reduced food intake and body weight in a dose-dependent manner with no evidence of tolerance to these effects.
D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D004174:Diprenorphine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D009019:Morphinans / Q000494:pharmacology*; D009270:Naloxone / Q000031:analogs & derivatives*; D009271:Naltrexone / Q000494:pharmacology*; D051381:Rats; D011957:Receptors, Opioid / Q000187:drug effects; D017473:Receptors, Opioid, kappa; D012453:Saimiri; D012472:Salivation / Q000187:drug effects
D009019:Morphinans; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D004174:Diprenorphine; D009270:Naloxone; D009271:Naltrexone